STOCK TITAN

NeOnc Reports Additional Partial Response in Phase 2a Study of Intranasal NEO100

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

NeOnc Technologies Holdings (NTHI) reported an additional partial response in its Phase 2a study of intranasal NEO100 for recurrent or progressive glioma. The interim RANO 2.0 objective response rate rose to 12.5% (3 of 24 patients) from 8.3% in the August 12, 2026 topline results. Patients had Grade III or IV IDH1-mutant glioma.

Previously reported six-month progression-free survival, the primary endpoint, was 48.9% versus a prespecified 20% historical benchmark; median overall survival was 26.1 months from treatment initiation at recurrence. Disease control was 66.7%. All reported treatment-related adverse events were Grade 1 or 2, with no treatment-related serious adverse events or discontinuations. The single-arm, open-label study had no randomized control group. Results differ under protocol-specified response criteria and estimation methods, and interim findings may change at final analysis.

Loading...
Loading translation...
5 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 5 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major pointSix-month progression-free survival was 48.9% versus the prespecified 20% historical benchmark (one-sided p = 0.0047).
  • Moderate pointObjective response rate reached 12.5% (3 of 24), versus 8.3% (2 of 24) in August, using RANO 2.0.
  • Moderate pointMedian overall survival was 26.1 months (95% CI, 8.5–27.1 months) from NEO100 treatment initiation at recurrence.
  • Minor pointStable disease occurred in 13 patients (54.2%) under RANO 2.0.
  • Minor pointTreatment-related adverse events included no serious events or treatment discontinuations.

Negative

  • Moderate pointSingle-arm, open-label design used a historical benchmark without a randomized control group.
  • Minor pointProgressive disease occurred in eight patients (33.3%) under RANO 2.0.
  • Minor pointTreatment-related adverse events were Grade 1 or 2, predominantly local nasal or upper-airway effects.
  • Minor pointResults differ under the response criteria and estimation method specified in the study protocol.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Interim results may change at final analysis.

Key Figures

Objective response rate: 12.5% (3 of 24 patients), compared with 8.3% (2 of 24 patients) Six-month progression-free survival: 48.9% (95% CI, 26.3%–68.1%); one-sided p = 0.0047 Median overall survival: 26.1 months (95% CI, 8.5–27.1 months) +2 more
Objective response rate
12.5% (3 of 24 patients), compared with 8.3% (2 of 24 patients)
Updated interim results vs. August topline; RANO 2.0
Six-month progression-free survival
48.9% (95% CI, 26.3%–68.1%); one-sided p = 0.0047
RANO 2.0; compared with the prespecified 20% historical benchmark
Median overall survival
26.1 months (95% CI, 8.5–27.1 months)
From the start of NEO100 treatment at recurrence
Disease control rate
66.7%
Updated interim results
Treatment-related adverse events
All reported events were Grade 1 or 2
Interim analysis

Previous Clinical trial Reports

1 past event · Latest: Aug 12
Same Type 1 event
  1. Aug 12

    Phase 2a results

    24h Move
    -20.5%

    August topline reported two objective responses among 24 patients under RANO 2.0 criteria.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

kaplan–meier estimation, idh1-mutant, open-label, single-arm
4 terms
kaplan–meier estimation medical
"by RANO 2.0 using Kaplan–Meier estimation"
A statistical method that estimates the probability that a specified event (commonly death, disease recurrence, equipment failure, or other ‘time-to-event’ outcomes) has not occurred by each time point, producing a stepwise survival curve from observed follow-up times. It accounts for censored observations—participants whose event time is unknown because they left the study or the study ended—by using the number at risk and the number of events at each event time to update the survival probability. It does not model effects of multiple covariates (that requires other methods such as a Cox model) and assumes censoring is non-informative (censored subjects have the same future risk as those remaining under observation).
idh1-mutant medical
"recurrent or progressive Grade III or Grade IV IDH1-mutant glioma"
An IDH1‑mutant is a version of the cellular enzyme IDH1 that has a specific genetic change causing it to act differently than normal. Like a light switch stuck halfway, the altered enzyme creates abnormal chemicals that can drive certain cancers and serve as a clear disease fingerprint. Investors watch IDH1‑mutant status because it creates opportunities for targeted drugs, diagnostic tests, and companion therapies that can change treatment pathways and company value.
open-label medical
"an open-label study of intranasal NEO100"
Open-label describes a situation where everyone involved in a study or process knows the full details, such as who is receiving a treatment or intervention. For investors, understanding whether a project or product is open-label helps gauge the level of transparency and potential biases, influencing trust and decision-making. It’s like knowing whether a test or experiment is conducted openly or behind closed doors.
single-arm medical
"The single-arm, open-label study used a historical benchmark"
A single-arm study is a clinical trial that gives all participants the same treatment and does not include a separate comparison group or placebo. Think of it like testing a new recipe by serving it to diners without offering a control dish — you can see how people respond, but you can’t directly compare results to another option. For investors, single-arm trials can speed development and reduce cost but leave more uncertainty about how a treatment stacks up against existing therapies and how regulators will view the evidence.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Objective response rate was 12.5% (3 of 24 patients) by RANO 2.0, compared with 8.3% (2 of 24 patients) in the August topline results

Median overall survival was 26.1 months from the start of NEO100 treatment at recurrence, as previously reported

CALABASAS, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today reported updated interim results from the Phase 2a portion of NEO100-01, an open-label study of intranasal NEO100 in patients with recurrent or progressive Grade III or Grade IV IDH1-mutant glioma. One additional partial response brought the objective response rate to 12.5% (3 of 24 patients), compared with 8.3% (2 of 24 patients) in the August 12, 2026 topline results. Both rates were assessed using RANO 2.0 criteria.

By RANO 2.0 criteria, three patients had a partial response (12.5%), 13 had stable disease (54.2%) and eight had progressive disease (33.3%). The disease control rate was 66.7%. Five patients remained on treatment at the interim database lock.

As previously reported, six-month progression-free survival, the study’s primary endpoint, was 48.9% (95% CI, 26.3%–68.1%) by RANO 2.0 using Kaplan–Meier estimation, compared with the prespecified 20% historical benchmark (one-sided p = 0.0047). Median overall survival was 26.1 months (95% CI, 8.5–27.1 months) from the start of NEO100 treatment at recurrence. The single-arm, open-label study used a historical benchmark and had no randomized control group. Results differ under the response criteria and estimation method specified in the study protocol. Interim results may change at final analysis.

“We are encouraged by the additional partial response in this update,” said Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer of NeOnc. “We remain focused on advancing the development of NEO100 for patients with recurrent high-grade glioma.”

At the interim analysis, all reported treatment-related adverse events were Grade 1 or 2 and consisted predominantly of local nasal or upper-airway effects. NeOnc reported no treatment-related serious adverse events or discontinuations due to treatment-related adverse events.

About the NEO100-01 Study

NEO100-01 is an open-label, multicenter Phase 1/2a study of intranasal NEO100 in patients with radiographically confirmed progression or recurrence of primary or secondary Grade IV glioma or Grade III astrocytoma harboring an IDH1 mutation. In Phase 2a, 28 patients received the recommended Phase 2 dose of 1,152 mg/day. The efficacy population consisted of 24 patients with IDH1-mutant tumors, including 21 with Grade IV disease. Enrollment is complete.

About NEO100

NEO100 is a highly purified form of perillyl alcohol administered intranasally. Its delivery approach is designed to provide a non-invasive route to the brain. NEO100 remains investigational, and its safety and efficacy have not been established. NEO100 has received Orphan Drug designation from the FDA for the treatment of gliomas.

About NeOnc Technologies Holdings, Inc.

NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company developing therapies for central nervous system cancers. Its investigational programs include intranasal NEO100 and oral NEO212. NEO212 has completed Phase 1 dose escalation and is advancing toward Phase 2 development. NeOnc exclusively licenses a worldwide portfolio of issued patents and pending applications from the University of Southern California related to NEO100, NEO212 and other drug candidates and delivery approaches. For more information, visit https://neonc.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding the interpretation and significance of the updated Phase 2a results, the Company’s clinical development programs and the clinical potential of NEO100 and NEO212. These statements reflect current expectations and involve risks and uncertainties. NEO100 and NEO212 are investigational, and neither has been approved by any regulatory authority. Future studies may not demonstrate safety or efficacy. Clinical development remains subject to applicable clinical, regulatory and institutional requirements, and no regulatory pathway or marketing approval is assured.

The NEO100 Phase 2a study was a single-arm, open-label study that was not powered as a confirmatory trial. The interim results may change at final analysis. Comparisons with historical benchmarks were made without a randomized control group. The efficacy results presented reflect RANO 2.0 criteria and Kaplan–Meier estimation, and results differ under the response criteria and estimation method specified in the study protocol. The Company will require substantial additional capital to fund its operations, which may not be available on acceptable terms or at all. Actual results may differ materially. Readers should consider the risk factors described in the Company’s most recent filings with the Securities and Exchange Commission. These statements speak only as of the date of this release. The Company undertakes no obligation to update forward-looking statements except as required by law.

“NEO100” and “NEO212” are registered trademarks of NeOnc Technologies Holdings, Inc.

Contacts

Company Contact
info@neonc.com

Investor Contact
Jon Nugent
Jon Nugent Communications
jon@jonnugent.com
205-566-3026

This press release was published by a CLEAR® Verified individual.


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did NeOnc's NEO100 Phase 2a update show about tumor responses?

The RANO 2.0 objective response rate reached 12.5% (3 of 24 patients), compared with 8.3% (2 of 24 patients) in the August 12, 2026 topline results. One additional partial response accounted for the increase. The disease control rate was 66.7%.

What was the primary endpoint result in NeOnc's NEO100 Phase 2a study?

Six-month progression-free survival was 48.9% (95% CI, 26.3%–68.1%), compared with the prespecified 20% historical benchmark (one-sided p = 0.0047). This previously reported primary endpoint result used RANO 2.0 criteria and Kaplan–Meier estimation, a method for estimating outcomes over time.

How many patients remained on NEO100 treatment at NeOnc's interim database lock?

Five patients remained on treatment at the interim database lock.

Keep reading